We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response. In total, 173 patients received 4 infusions of 375 mg/m(2) and 72 received 2 fixed 1-g infusions 2 weeks apart. The choice of the rituximab regimen was based on the physician's preference and not patient characteristics. Overall, 38 patients showed minor intolerance to rituximab infusions; infusions had to be stopped for only 3 patients. Seven showed infection (n = 11 cases), with an incidence of 2.3 infections/100 patient-years. Three patients died of infection 12 to 14 months after rituximab infusions, but the role of rituximab was questionable. In total, 152 patients (61%) showed an overall initial response (platelet count ≥30 × 10(9)/L and ≥2 baseline value). At a median follow-up of 24 months, 96 patients (39%) showed a lasting response. On multivariate analysis, the probability of sustained response at 1 year was significantly associated with ITP duration <1 year (P = .02) and previous transient complete response to corticosteroids (P = .05). The pattern of response was similar with the 2 rituximab regimens. With its benefit/risk ratio, rituximab used off-label may remain a valid option for treating persistent or chronic ITP in adults. This trial was registered at www.clinicaltrials.gov as #NC1101295.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2014-06-582346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune thrombocytopenia (ITP) is an autoimmune disorder marked by a low platelet count, leading to symptoms ranging from mild to severe bleeding. It can be triggered by various factors, including idiopathic origins, medications, malignancies, infections, and other autoimmune conditions. Though rare, ITP can also occur postvaccination.
View Article and Find Full Text PDFAnalysis of Risk Factors and the Establishment of a Predictive Model for Thrombosis in Patients with Immune Thrombocytopenia.
Clin Appl Thromb Hemost
January 2025
Department of Rheumatology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan Province Clinical Research Center for Hematologic Disease, Kunming, Yunnan, China.
Objectives: To explore the risk factors for thrombi occurring in patients with immune thrombocytopenia (ITP) and establish a risk prediction model to better predict the risk of thrombosis in patients with ITP.
Methods: We retrospectively analyzed 350 ITP patients who had been hospitalized in the First People's Hospital of Yunnan Province between January 2024 and June 2024. For all patients, we recorded demographic characteristics and clinical data, analyzed the risk factors for thrombosis in ITP patients and then developed a risk prediction model.
Dengue Fever in an Adult Presenting as Immune Thrombocytopenic Purpura (ITP): A Case Report.
Cureus
December 2024
General Medicine, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND.
Article Synopsis
- Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to low platelet counts, mostly seen in children after viral infections, while adults may develop chronic ITP.
- In adults, though rare, ITP can occur following viral infections like dengue fever, with symptoms typically showing up towards the end of the first week of illness.
- A case study of a woman in her forties experiencing ITP as a primary symptom of dengue fever illustrates the necessity for early diagnosis and proper treatment, underscoring ITP as a potential complication of viral infections.
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Progesterone Regulates Gut Microbiota Mediating Bone Marrow MSCs Injury in ITP Patients during Pregnancy.
J Thromb Haemost
January 2025
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; National Clinical Research Center for Hematologic Disease, Beijing, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, China; Clinical Research Center for Hematologic Disease, Beijing, China. Electronic address:
Background: Immune thrombocytopenia during pregnancy (PITP) is the most common cause of platelet reduction in early and mid-pregnancy. However, the pathogenesis of PITP is still unclear.
Objectives: To determine the characteristics of bone marrow mesenchymal stem cells (BM-MSCs) in PITP patients and to explore the associations between metabolites, the gut microbiota, and BM-MSCs in PITP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!